Weijia Wang
Impact in
-
- CAR-T cell therapy research
-
- Systemic Lupus Erythematosus Research
Papers in
- Co-authors
- Yong Yuan (1 shared paper)JoAnn Suzich (1 shared paper)Xing Cheng (1 shared paper)Hong-Ryul Jin (1 shared paper)Qi Xu (1 shared paper)Mark S. Galinski (1 shared paper)James A. Harper (1 shared paper)Danielle K. Carroll (1 shared paper)
In The Last Decade
Weijia Wang
13 papers receiving 339 citations
Weijia Wang's Hit Papers
Peers
Comparison fields: 5 of 41
- Oncology 127
- Rheumatology 56
- Genetics 47
- Immunology 25
- Developmental Neuroscience 4
Countries citing papers authored by Weijia Wang
This map shows the geographic impact of Weijia Wang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Weijia Wang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Weijia Wang more than expected).
Fields of papers citing papers by Weijia Wang
This network shows the impact of papers produced by Weijia Wang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Weijia Wang. The network helps show where Weijia Wang may publish in the future.
Co-authors
The 25 scholars most cited alongside Weijia Wang, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open-label clinical trial Hit paper breakdown → | 2024 | 155 |
| 2 | 2016 | 52 | |
| 3 | 2022 | 37 | |
| 4 | 2013 | 25 | |
| 5 | 2021 | 24 | |
| 6 | 2018 | 14 | |
| 7 | 2020 | 13 | |
| 8 | 2021 | 12 | |
| 9 | 2025 | 9 | |
| 10 | 2022 | 6 | |
| 11 | A novel immune-related gene signature correlated with serum IL33 expression in acute myeloid leukemia prognosis. | 2023 | 3 |
| 12 | 2024 | 2 | |
| 13 | 2016 | 1 |
About Weijia Wang
Weijia Wang is a scholar working on Oncology, Genetics, Physiology, Microbiology and Biotechnology, having authored 13 papers that have together received 353 indexed citations. Recurring topics across this work include CAR-T cell therapy research (2 papers), Developmental Biology and Gene Regulation (2 papers), Antimicrobial Peptides and Activities (1 paper), Epigenetics and DNA Methylation (1 paper), Down syndrome and intellectual disability research (1 paper), Pluripotent Stem Cells Research (1 paper), Cancer Cells and Metastasis (1 paper) and Acute Myeloid Leukemia Research (1 paper). The work is most often cited by research in Oncology (127 citations), Rheumatology (56 citations), Genetics (47 citations), Immunology (25 citations) and Developmental Neuroscience (4 citations). Weijia Wang has collaborated with scholars based in China and Australia. Frequent co-authors include Yong Yuan, JoAnn Suzich, Xing Cheng, Hong-Ryul Jin, Qi Xu, Mark S. Galinski, James A. Harper, Danielle K. Carroll, Wenjun Liu and Jianping He. Their work appears in journals such as Cell Death and Disease, Stem Cell Reviews and Reports, BMC Pediatrics, Gene and CHEST Journal.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.